VIKING-MALT-GROUP
30.8.2021 14:43:06 CEST | Business Wire | Press release
Marcin Siemion has decided to leave the Viking Malt Group. He has over many years successfully developed the Viking Malt Polish business and been a key contributor to creating a strong commercial position for Viking Malt Group in the international malting industry. We thank him for his contribution to the company and wish him all the best both privately and professionally. Following this, we would like to announce the following changes in Viking Malt Sales organization:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005352/en/
Malin Andersson has been appointed VP Sales in Viking Malt Group
Malin Andersson will be responsible for the sales strategy and the volume customers. She will become a member of the Group Management Team and in her role help Viking Malt in its mission of providing value-adding malted products to our customers for their success. Malin has been with the company since 1997, successfully leading sales, marketing, customer service and logistics in Viking Malt Sweden as well as had the role of a Site Manager and as latest also the role of Managing Director of Viking Malt Sweden. She has in depth knowledge of the company and the industry with a wide international network in malting and brewing industry. She holds an Executive MBA from Copenhagen Business School.
Annika Wilhelmson will lead the Craft and Partner Sales
At the same time, we have the pleasure to announce that Annika Wilhelmson will be responsible for the Craft and Partner Sales and Marketing. She will continue her work in the Group Management Team and cover Innovation, Quality and CSR in the Vice President role. Annika started with Viking Malt Group in 2017 as VP New Business Development. She holds a doctor´s degree in chemical engineering from Helsinki University of Technology and is specialized in malting. Prior to Viking Malt she has worked at VTT in several roles including senior scientist, project manager and Key Account Manager responsible for sales.
Tomasz Malec appointed Viking Malt Poland Managing Director
VP Supply Chain Tomasz Malec will take over the role of the MD of the Viking Malt Polish entity. He continues in his role as the VP Supply Chain and as the member of the Management Team for the Group.
Before Viking Malt Tomasz Malec worked for Carlsberg for almost twenty years, latest as the VP Production for Carlsberg Poland. Prior to Carlsberg he has worked for Elkometech, Danfoss and Computerland SA as well as Huta Auluminimum Konin SA in different roles. Tomasz holds a degree in engineering from Łódź Technical University, Poland.
“I am delighted to offer these important roles to three of our key leaders. I feel confident that we will continue to serve our customers around the world with high quality malt - and secure that the company with over 130 years of history will stay strong for many years to come“, says CEO Kasper Madsen.
Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark and Lithuania as well as two plants in Poland. The production capacity is 600 000 t/a and the turnover of the group is appr. 250 million euros and the company employ appr. 260 employees. Viking Malt is the largest malting company in Scandinavia, 5th largest in Europe and 9th in the world. It is the leading company in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210830005352/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
